CIK 0001517022 · Large accelerated filer
Akebia Therapeutics, Inc.
Sign in to watch- Ticker
- AKBA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208756903
- Phone
- 617-871-2098
- Business address
- 180 THIRD AVENUE, FLOOR 2, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 34 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-02-21 | Amello Jason SVP, CFO & Treasurer | Grant or award | +30,000 | 65,637 | ||
| 2017-02-21 | Amello Jason SVP, CFO & Treasurer | Grant or award · Stock Option (Right to buy) | +47,500 | $10.14 | $482K | 47,500 |
| 2017-01-19 | Butler John P. CEO and President | Option exercise | +20,000 | $0.47 | $9K | 373,480 |
| 2017-01-19 | Butler John P. CEO and President | Option exercise · Stock Option (Right to buy) | −20,000 | 387,000 | ||
| 2017-01-03 | Nash Duane Director | Sale | −1,980 | $10.46 | $21K | 25,668 |
| 2017-01-01 | Dahan Michel SVP, Chief Business Officer | Sale | −1,629 | $10.49 | $17K | 70,524 |
| 2017-01-01 | Hadas Nicole R. SVP, General Counsel, Sec. | Sale | −1,810 | $10.49 | $19K | 82,912 |
| 2016-11-30 | Tubridy Karen L SVP, Chief Development Officer | Grant or award · Stock Option (Right to buy) | +130,000 | 130,000 | ||
| 2016-10-03 | Nash Duane Director | Sale | −1,981 | $8.96 | $18K | 27,648 |
| 2016-10-01 | Dahan Michel SVP, Chief Business Officer | Sale | −1,401 | $8.95 | $13K | 72,153 |
| 2016-10-01 | Hadas Nicole R. SVP, General Counsel, Sec. | Sale | −1,556 | $8.95 | $14K | 83,915 |
| 2016-07-29 | Canute Scott A Director | Grant or award · Stock Option (Right to buy) | +25,000 | 25,000 | ||
| 2016-07-06 | Nash Duane Director | Sale | −1,980 | $7.48 | $15K | 29,629 |
| 2016-07-05 | Dahan Michel SVP, Chief Business Officer | Sale | −1,402 | $7.47 | $10K | 73,554 |
| 2016-07-05 | Hadas Nicole R. SVP, General Counsel, Sec. | Sale | −1,557 | $7.47 | $12K | 85,471 |
| 2016-06-16 | WYZGA MICHAEL S Director | Grant or award · Stock Option (Right to buy) | +12,500 | 12,500 | ||
| 2016-06-16 | Satter Muneer A Director | Grant or award · Stock Option (Right to buy) | +12,500 | 12,500 | ||
| 2016-06-16 | Renaud Ronald C JR Director | Grant or award · Stock Option (Right to buy) | +12,500 | 12,500 | ||
| 2016-06-16 | Nash Duane Director | Grant or award · Stock Option (Right to buy) | +12,500 | 12,500 | ||
| 2016-06-16 | GOWEN MAXINE Director | Grant or award · Stock Option (Right to buy) | +12,500 | 12,500 |
Page 24 of 27 · 537 trades